|
|
|
|
 |
|
 |
|
* ½ÉÇ÷°ü »ç°ÇÀÇ ÀÏÂ÷ ¿¹¹æÀ» À§ÇÑ ¾Æ½ºÇǸ° »ç¿ë
U.S. Preventive Services Task Force (USPSTF)´Â ¾Æ½ºÇǸ°ÀÇ »ç¿ë¿¡ ´ëÇÑ È¿´É°ú À¯Çظ¦ Æò°¡ÇÏ¿© È¿´ÉÀÌ ³ôÀ» °æ¿ì ¾Æ½ºÇǸ°À» »ç¿ëÇÒ °ÍÀ» ±Ç°íÇϰí ÀÖ´Ù. ¼öÁýµÈ ¸ÞŸºÐ¼® µ¥ÀÌÅÍ¿¡ ÀÇÇÏ¸é ¾Æ½ºÇǸ° ¿ä¹ýÀÌ °üµ¿¸Æ ½ÉÁúȯÀÇ À§ÇèÀ» 28%(summary odds ratio, 0.72[95% CI, 0.60-0.87])±îÁö ³·Ãß´Â °ÍÀÌ Áõ¸íµÇ¾ú°í, ÀÌ·¯ÇÑ È¿´ÉÀº °üµ¿¸Æ ½ÉÁúȯÀÇ °íÀ§Çè ȯÀÚ(5³â À§Çè·üÀÌ 3% ÀÌ»ó)¿¡¼ ´õ µÎµå·¯Á³´Ù.
|
|
|
|
|
| References.
|
|
1. Mosca L, Banka C, Benjamin E, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. Circulation 2007: March 2007.
|
|
| 2. Buse JB, Ginsberg HN, Bakris GL, et al. Primary Prevention of Cardiovascular Diseases in People with Diabetes Mellitus. Circulation 2007;115:114-126.
|
|
| 3. Sacco RL, Adams R, Albers G, et al. Guidelines for Prevention of Stroke in Patients with Ischemic Stroke or Transient Ischemic Attack. Circulation 2006;113:e409-e449.
|
|
| 4. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Circulation 2002;106:388-391.
|
|
| 5. Pignone M, Earnshaw S, Pletcher M, et al. Aspirin for the primary prevention of cardiovascular disease in women; A cost-utility analysis. Arch Intern Med 2007; 167: 290-295.
|
|
|
 |